Stop ignoring presbyopia eye drops.

The article addresses the cautious reception of presbyopia eye drops, such as Vuity (pilocarpine HCl ophthalmic solution 1.25%, AbbVie), among eye care professionals since their 2021 approval. It highlights that while these drops have some side effects and require patient adjustment, serious risks like retinal detachment are extremely rare and not definitively linked to the medication. The author emphasizes the importance of clinicians actively recommending these drops, as they meet patient demand for reduced dependence on glasses and can foster patient loyalty and further innovation in presbyopia treatments. Understanding individual patient responses to different drops is crucial for optimizing outcomes and encouraging the development of improved therapies.